[1]
Bhatt, A.P.; Redinbo, M.R.; Bultman, S.J. The role of the microbiome in cancer development and therapy. CA Cancer J. Clin., 2017, 67(4), 326-344.
[3]
Tian, J.; Min, Y.; Rodgers, Z.; Au, K.M.; Hagan, C.T.; Zhang, M.; Roche, K.; Yang, F.; Wagner, K.; Wang, A.Z. Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. J. Mater. Chem. B Mater. Biol. Med., 2017, 5, 6049-6057.
[4]
Guo, G.; Tortorella, M.; Zhang, B.; Wang, Y. Disassembly of micelle-like polyethylenimine nanocomplexes for siRNA delivery: High transfection efficiency and reduced toxicity achieved by simple reducible lipid modification. J. Colloid Interface Sci., 2017, 504, 633-644.
[5]
Tian, L.; Bae, Y.H. Cancer nanomedicines targeting tumor extracellular pH. Colloids Surf. B Biointerfaces, 2012, 99, 116-126.
[6]
Gao, Z.; Zhang, L.; Sun, Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release, 2012, 162, 45-55.
[7]
Al-Yasiri, A.Y.; Khoobchandani, M.; Cutler, C.S.; Watkinson, L.; Carmack, T.; Smith, C.J.; Kuchuk, M.; Loyalka, S.K.; Lugão, A.B.; Katti, K.V. Mangiferin functionalized radioactive gold nanoparticles (MGF-(198)AuNPs) in prostate tumor therapy: Green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy. Dalton Trans., 2017, 46(42), 1456-1471.
[8]
Roy, A.; Li, S.D. Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2016, 8(6), 891-908.
[9]
Witz, I.P. The tumor microenvironment: the making of a paradigm. Cancer Microenviron., 2009, 2(Suppl. 1), 9-17.
[10]
Muntimadugu, E.; Kommineni, N.; Khan, W. Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. Pharmacol. Res., 2017, (126), 109-122.
[11]
Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol., 2007, 9, 654-659.
[12]
Zou, W.; Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol., 2008, 8, 467-477.
[13]
Yu, H.; Kortylewski, M.; Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol., 2007, 7, 41-51.
[14]
Pahl, J.; Cerwenka, A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology, 2017, 222, 11-20.
[15]
Spaks, A. Role of CXC group chemokines in lung cancer development and progression. J. Thorac. Dis., 2017, 9, S164-S171.
[16]
Persano, L.; Rampazzo, E.; Basso, G.; Viola, G. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem. Pharmacol., 2013, 85, 612-622.
[17]
Xin, Y.; Huang, M.; Guo, W.W.; Huang, Q.; Zhang, L.Z.; Jiang, G. Nano-based delivery of RNAi in cancer therapy. Mol. Cancer, 2017, 16, 134.
[18]
Kang, B.; Kukreja, A.; Song, D.; Huh, Y.M.; Haam, S. Strategies for using nanoprobes to perceive and treat cancer activity: A review. J. Biol. Eng., 2017, 11, 13.
[19]
Ji, T.; Zhao, Y.; Ding, Y.; Nie, G. Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. Adv. Mater.Weinheim, 2013, 25, 3508-3525.
[20]
Upreti, M.; Jyoti, A.; Sethi, P. Tumor microenvironment and nanotherapeutics. Transl. Cancer Res., 2013, 2, 309-319.
[21]
Huang, S.; Shao, K.; Liu, Y.; Kuang, Y.; Li, J.; An, S.; Guo, Y.; Ma, H.; Jiang, C. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano, 2013, 7, 2860-2871.
[22]
Luciano, R.; Battafarano, G.; Saracino, R.; Rossi, M.; Perrotta, A.; Manco, M.; Muraca, M.; Del Fattore, A. New perspectives in glioblastoma: nanoparticles-based approaches. Curr. Cancer Drug Targets, 2017, 17, 203-220.
[23]
Park, J.; Wrzesinski, S.H.; Stern, E.; Look, M.; Criscione, J.; Ragheb, R.; Jay, S.M.; Demento, S.L.; Agawu, A.; Licona, L.P.; Ferrandino, A.F.; Gonzalez, D.; Habermann, A.; Flavell, R.A.; Fahmy, T.M. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater., 2012, 11, 895-905.
[24]
Feczkó, T.; Fodor-Kardos, A.; Sivakumaran, M.; Haque, S.Q.T. In vitro IFN-α release from IFN-α- and pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and pegylated poly(lactic-co-glycolic acid) nanoparticles. Nanomedicine (Lond), 2016, 11, 2029-2034.
[25]
Shvedova, A.A.; Tkach, A.V.; Kisin, E.R.; Khaliullin, T.; Stanley, S.; Gutkin, D.W.; Star, A.; Chen, Y.; Shurin, G.V.; Kagan, V.E.; Shurin, M.R. Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. Small, 2013, 9, 1691-1695.
[26]
Nakamura, Y.; Mochida, A.; Choyke, P.L.; Kobayashi, H. Nanodrug delivery: Is the enhanced permeability and retention effect sufficient for curing cancer. Bioconjug. Chem., 2016, 27, 2225-2238.
[27]
Adiseshaiah, P.P.; Hall, J.B.; McNeil, S.E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2010, 2, 99-112.
[28]
Lee, K.Y.; Lee, G.Y.; Lane, L.A.; Li, B.; Wang, J.; Lu, Q.; Wang, Y.; Nie, S. Functionalized, long-circulating, and ultrasmall gold nanocarriers for overcoming the barriers of low nanoparticle delivery efficiency and poor tumor penetration. Bioconjug. Chem., 2017, 28, 244-252.
[29]
Stylianopoulos, T.; Jain, R.K. Design considerations for nanotherapeutics in oncology. Nanomedicine , 2015, 11, 1893-1907.
[30]
Wong, C.; Stylianopoulos, T.; Cui, J.; Martin, J.; Chauhan, V.P.; Jiang, W.; Popovic, Z.; Jain, R.K.; Bawendi, M.G.; Fukumura, D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. USA, 2011, 108, 2426-2431.
[31]
Carter, T.; Mulholland, P.; Chester, K. Antibody-targeted nanoparticles for cancer treatment. Immunotherapy, 2016, 8, 941-958.
[32]
Akhtar, M.J.; Ahamed, M.; Alhadlaq, H.A.; Alrokayan, S.A.; Kumar, S. Targeted anticancer therapy: Overexpressed receptors and nanotechnology. Clin. Chim. Acta, 2014, 436, 78-92.
[33]
Kaur, S.; Prasad, C.; Balakrishnan, B.; Banerjee, R. Trigger responsive polymeric nanocarriers for cancer therapy. Biomater. Sci., 2015, 3, 955-987.
[34]
Du, J.Z.; Mao, C.Q.; Yuan, Y.Y.; Yang, X.Z.; Wang, J. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnol. Adv., 2014, 32, 789-803.
[35]
Zhu, J.; Liao, L.; Bian, X.; Kong, J.; Yang, P.; Liu, B. pH-controlled delivery of doxorubicin to cancer cells, based on small mesoporous carbon nanospheres. Small, 2012, 8, 2715-2720.
[36]
Qian, W.Y.; Sun, D.M.; Zhu, R.R.; Du, X.L.; Liu, H.; Wang, S.L. pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release. Int. J. Nanomedicine, 2012, 7, 5781-5792.
[37]
Kanamala, M.; Wilson, W.R.; Yang, M.; Palmer, B.D.; Wu, Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. Biomaterials, 2016, 85, 152-167.
[38]
Corbet, C.; Feron, O. Tumour acidosis: From the passenger to the driver’s seat. Nat. Rev. Cancer, 2017, 17(10), 577-593.
[39]
Nakazawa, M.S.; Keith, B.; Simon, M.C. Oxygen availability and metabolic adaptations. Nat. Rev. Cancer, 2016, 16(10), 663-673.
[40]
Scheuermann, T.H.; Li, Q.; Ma, H.W.; Key, J.; Zhang, L.; Chen, R.; Garcia, J.A.; Naidoo, J.; Longgood, J.; Frantz, D.E.; Tambar, U.K.; Gardner, K.H.; Bruick, R.K. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat. Chem. Biol., 2013, 9(4), 271-276.
[41]
Pourmorteza, M.; Rahman, Z.U.; Young, M. Evofosfamide, a new horizon in the treatment of pancreatic cancer. Anticancer Drugs, 2016, 27(8), 723-725.
[42]
Lohse, I.; Rasowski, J.; Cao, P.; Pintilie, M.; Do, T.; Tsao, M.S.; Hill, R.P.; Hedley, D.W. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. Oncotarget, 2016, 7(23), 33571-33580.
[43]
Torosean, S.; Flynn, B.; Axelsson, J.; Gunn, J.; Samkoe, K.S.; Hasan, T.; Doyley, M.M.; Pogue, B.W. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomedicine , 2013, 9, 151-158.
[44]
Singh, Y.; Pawar, V.K.; Meher, J.G.; Raval, K.; Kumar, A.; Shrivastava, R.; Bhadauria, S.; Chourasia, M.K. Targeting tumor associated macrophages (TAMs) via nanocarriers. J. Control. Release, 2017, 254, 92-106.
[45]
Wang, Y.; Lin, Y.X.; Qiao, S.L.; An, H.W.; Ma, Y.; Qiao, Z.Y.; Rajapaksha, R.P.; Wang, H. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials, 2017, 112, 153-163.
[46]
Wang, T.; Shigdar, S.; Shamaileh, H.A.; Gantier, M.P.; Yin, W.; Xiang, D.; Wang, L.; Zhou, S.F.; Hou, Y.; Wang, P.; Zhang, W.; Pu, C.; Duan, W. Challenges and opportunities for siRNA-based cancer treatment. Cancer Lett., 2017, 387, 77-83.
[47]
Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release, 2010, 148, 135-146.
[48]
Ruan, S.; He, Q.; Gao, H. Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma. Nanoscale, 2015, 7, 9487-9496.
[49]
Pastorino, L.; Erokhina, S.; Caneva-Soumetz, F.; Ruggiero, C. Paclitaxel-containing nano-engineered polymeric capsules towards cancer therapy. J. Nanosci. Nanotechnol., 2009, 9, 6753-6759.
[50]
Yim, H.; Park, S.J.; Bae, Y.H.; Na, K. Biodegradable cationic nanoparticles loaded with an anticancer drug for deep penetration of heterogeneous tumours. Biomaterials, 2013, 34, 7674-7682.
[51]
Lee, Y.; Thompson, D.H. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2017, 9(5), e1450.
[52]
Sassaroli, E.; Li, K.C.; O’Neill, B.E. Numerical investigation of heating of a gold nanoparticle and the surrounding microenvironment by nanosecond laser pulses for nanomedicine applications. Phys. Med. Biol., 2009, 54, 5541-5560.
[53]
Cheng, R.; Meng, F.; Deng, C.; Klok, H.A.; Zhong, Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials, 2013, 34, 3647-3657.
[54]
Shao, Y.; Fu, J. Integrated micro/nanoengineered functional biomaterials for cell mechanics and mechanobiology: a materials perspective. Adv. Mater.Weinheim, 2014, 26, 1494-1533.
[55]
Zhu, L.; Torchilin, V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr. Biol., 2013, 5, 96-107.
[56]
Spencer, D.S.; Puranik, A.S.; Peppas, N.A. Intelligent nanoparticles for advanced drug delivery in cancer treatment. Curr. Opin. Chem. Eng., 2015, 7, 84-92.
[57]
Liu, Y.; Ding, X.; Li, J.; Luo, Z.; Hu, Y.; Liu, J.; Dai, L.; Zhou, J.; Hou, C.; Cai, K. Enzyme responsive drug delivery system based on mesoporous silica nanoparticles for tumor therapy in vivo. Nanotechnology, 2015, 26, 145102.
[58]
Chen, W.H.; Luo, G.F.; Lei, Q.; Cao, F.Y.; Fan, J.X.; Qiu, W.X.; Jia, H.Z.; Hong, S.; Fang, F.; Zeng, X.; Zhuo, R.X.; Zhang, X.Z. Rational design of multifunctional magnetic mesoporous silica nanoparticle for tumor-targeted magnetic resonance imaging and precise therapy. Biomaterials, 2016, 76, 87-101.
[59]
Chen, Y.; Ye, D.; Wu, M.; Chen, H.; Zhang, L.; Shi, J.; Wang, L. Break-up of two-dimensional MnO2 nanosheets promotes ultrasensitive pH-triggered theranostics of cancer. Adv. Mater.Weinheim, 2014, 26, 7019-7026.
[60]
Krishnamurthy, S.; Vaiyapuri, R.; Zhang, L.; Chan, J.M. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater. Sci., 2015, 3, 923-936.
[61]
Suarato, G.; Li, W.; Meng, Y. Role of pH-responsiveness in the design of chitosan-based cancer nanotherapeutics: A review.Biointerphases, 2016. 11, 04B201.
[62]
Curtis, L.T.; Frieboes, H.B. The Tumor Microenvironment as a Barrier to Cancer Nanotherapy. Adv. Exp. Med. Biol., 2016, 936, 165-190.
[63]
Jhaveri, A.; Deshpande, P.; Torchilin, V. Stimuli-sensitive nanopreparations for combination cancer therapy. J. Control. Release, 2014, 190, 352-370.
[64]
van de Ven, A.L.; Wu, M.; Lowengrub, J.; McDougall, S.R.; Chaplain, M.A.; Cristini, V.; Ferrari, M.; Frieboes, H.B. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv., 2012, 2, 11208.
[65]
Jahangirian, H.; Lemraski, E.G.; Webster, T.J.; Rafiee-Moghaddam, R.; Abdollahi, Y. A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine. Int. J. Nanomedicine, 2017, 12, 2957-2978.
[66]
Fonseca, N.A.; Gregório, A.C.; Valério-Fernandes, A.; Simões, S.; Moreira, J.N. Bridging cancer biology and the patients’ needs with nanotechnology-based approaches. Cancer Treat. Rev., 2014, 40, 626-635.
Download PDF Flyer